Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AutoCanada Inc. stock logo
ACQ
AutoCanada
C$22.39
+3.8%
C$19.43
C$13.75
C$23.27
C$521.05M2.5423,470 shs42,424 shs
EINC
VanEck Energy Income ETF
$97.16
+1.0%
$95.89
$76.99
$104.70
$84.02M0.786,706 shs1,946 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AutoCanada Inc. stock logo
ACQ
AutoCanada
-0.78%-0.92%+2.91%+24.02%+10.10%
EINC
VanEck Energy Income ETF
-0.66%-0.76%+0.32%-5.25%+23.75%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AutoCanada Inc. stock logo
ACQ
AutoCanada
2.0347 of 5 stars
1.30.01.70.03.22.51.9
EINC
VanEck Energy Income ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.2675 of 5 stars
0.00.00.04.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AutoCanada Inc. stock logo
ACQ
AutoCanada
2.50
Moderate BuyC$20.31-9.31% Downside
EINC
VanEck Energy Income ETF
2.61
Moderate Buy$97.16N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ACQ, EINC, and GBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
AutoCanada Inc. stock logo
ACQ
AutoCanada
CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ NeutralC$15.00 ➝ C$23.00
5/22/2025
AutoCanada Inc. stock logo
ACQ
AutoCanada
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuyC$22.00 ➝ C$24.00
5/15/2025
AutoCanada Inc. stock logo
ACQ
AutoCanada
Cibc World Mkts
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
3/27/2025
AutoCanada Inc. stock logo
ACQ
AutoCanada
ATB Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector PerformC$18.00 ➝ C$18.50
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AutoCanada Inc. stock logo
ACQ
AutoCanada
C$6.16B0.08C$3.53 per share6.34C$22.62 per share0.99
EINC
VanEck Energy Income ETF
N/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AutoCanada Inc. stock logo
ACQ
AutoCanada
-C$50.70M-C$2.17N/A0.30-0.82%-9.79%2.67%N/A
EINC
VanEck Energy Income ETF
N/AN/A18.74N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AutoCanada Inc. stock logo
ACQ
AutoCanada
C$0.401.79%N/AN/A N/A
EINC
VanEck Energy Income ETF
$2.913.00%N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AutoCanada Inc. stock logo
ACQ
AutoCanada
451.54
1.03
0.25
EINC
VanEck Energy Income ETF
N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17

Institutional Ownership

CompanyInstitutional Ownership
AutoCanada Inc. stock logo
ACQ
AutoCanada
50.90%
EINC
VanEck Energy Income ETF
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AutoCanada Inc. stock logo
ACQ
AutoCanada
4.90%
EINC
VanEck Energy Income ETF
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AutoCanada Inc. stock logo
ACQ
AutoCanada
2,55023.27 millionN/ANot Optionable
EINC
VanEck Energy Income ETF
N/A864,720N/ANot Optionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable

Recent News About These Companies

GBT LIVE! with Faye Donald
Global Blood Therapeutics Inc (GBT)
US judge schedules Amex GBT-CWT merger trial for September
US DOJ files lawsuit to block Amex GBT acquisition of CWT
U.S. Justice Department sues to block Amex GBT-CWT deal
US Files Antitrust Suit to Block Amex GBT-CWT Travel Merger (2)
GBT Technologies to acquire Nexus Workspaces from CGI
CT Partners appoint CEO to Advantage GBT Advisory Board
GBT, Robinson Properties to Develop Mixed-Use Project in Metro Nashville
GBT heads to FDA with sickle cell drug voxelotor

Media Sentiment Over Time

Top Headlines

View All Headlines
AutoCanada stock logo

AutoCanada TSE:ACQ

C$22.39 +0.81 (+3.75%)
As of 04:00 PM Eastern

AutoCanada Inc., through its subsidiaries, operates franchised automobile dealerships and related business. The company offers a range of automotive products and services, including new and used vehicles, vehicle leasing, vehicle parts, vehicle maintenance and collision repair services, and extended service contracts; and vehicle protection, after-market products, and auction services. It also arranges financing and insurance for vehicle purchases by its customers through third-party finance and insurance sources. The company sells its vehicles under the Chrysler, Dodge, Jeep, Ram, FIAT, Alfa Romeo, Chevrolet, GMC, Buick, Cadillac, Infiniti, Nissan, Hyundai, Subaru, Audi, Volkswagen, Mazda, Mercedes-Benz, BMW, MINI, Ford, Acura, Honda, Kia, and Porsche brands. It operates franchised dealerships in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, and New Brunswick in Canada, as well as in Illinois, the United States. The company also offers used vehicles online. AutoCanada Inc. was incorporated in 2009 and is based in Edmonton, Canada.

VanEck Energy Income ETF NYSEARCA:EINC

$97.16 +0.92 (+0.96%)
As of 04:10 PM Eastern

The VanEck Energy Income ETF (EINC) is an exchange-traded fund that mostly invests in energy equity. The fund tracks a market cap-weighted index of North American companies in midstream energy segments. EINC was launched on Mar 13, 2012 and is managed by VanEck.

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.